Use of Kalydeco in Children Ages 2 to 5: Vertex today announced the submission of an NDA in the United States for the approval of Kalydeco in children with CF ages 2 to 5 who have one of the following nine mutations in the CFTR gene: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D. Vertex also expects to complete the MAA line extension application in Europe this week. In the United States and Europe, Kalydeco is currently approved for use in people with CF ages 6 and older who have one of these nine mutations.
Great news for the little toddlers needing Kalydeco!
Source: http://t.co/rRhVoJvEBu
- Chris
Great news for the little toddlers needing Kalydeco!
Source: http://t.co/rRhVoJvEBu
- Chris